Page last updated: 2024-12-11
radolmidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
radolmidine: an alpha2-adrenergic agonist; radolmidine is the HCl salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6433098 |
CHEMBL ID | 2104262 |
SCHEMBL ID | 2641380 |
MeSH ID | M0396305 |
Synonyms (20)
Synonym |
---|
L001565 |
3-(1h-imidazol-5-ylmethyl)-2,3-dihydro-1h-inden-5-ol |
fadolmidine |
radolmidine |
3-(imidazol-4-ylmethyl)-5-indanol |
fadolmidine [inn] |
radolmidine [inn] |
wln5fgh1cy , |
unii-wln5fgh1cy |
189353-31-9 |
CHEMBL2104262 |
fadolmidine [who-dd] |
SCHEMBL2641380 |
3-(1h-imidazol-4-ylmethyl)-indan-5-ol |
VTZPAJGVRWKMAG-UHFFFAOYSA-N |
3-((1h-imidazol-5-yl)methyl)-2,3-dihydro-1h-inden-5-ol |
3-(1h-imidazol-4-ylmethyl)indan-5-ol |
Q27292710 |
SY356232 |
3-[(5-imidazolyl)methyl]indane-5-ol |
Research Excerpts
Overview
Radolmidine is a novel alpha2-adrenoceptor agonist with a different pharmacokinetic profile compared with the well-researched dexmedetomidine.
Excerpt | Reference | Relevance |
---|---|---|
"Radolmidine is a novel alpha2-adrenoceptor agonist with a different pharmacokinetic profile compared with the well-researched dexmedetomidine." | ( Effects of radolmidine, a novel alpha2 -adrenergic agonist compared with dexmedetomidine in different pain models in the rat. Kalso, E; Kontinen, VK; Xu, M, 2000) | 1.42 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.55) | 18.2507 |
2000's | 15 (68.18) | 29.6817 |
2010's | 2 (9.09) | 24.3611 |
2020's | 4 (18.18) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.49
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.49) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.55%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (95.45%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |